Table 1.
Proportion of patients exacerbating during the follow-up period, with patients categorised by exacerbation history and eosinophil count
| Patients (%) | Group 1 Low exacerbations and high eosinophils |
Group 2 High exacerbations and high eosinophils |
Group 3 Low exacerbations and low eosinophils |
Group 4 High exacerbations and low eosinophils |
Total |
|---|---|---|---|---|---|
| Overall population | (N = 190) | (N = 53) | (N = 158) | (N = 29) | (N = 430) |
| No exacerbation | 137 (72.1) | 27 (50.9) | 117 (74.1) | 15 (51.7) | 296 (68.8) |
| One or more exacerbation | 41 (21.6) | 26 (49.1) | 35 (22.2) | 13 (44.8) | 115 (26.7) |
| Missing values | 12 (6.3) | 0 | 6 (3.8) | 1 (3.4) | 19 (4.4) |
| LABA/LAMA fixed–dose combination group | (N = 50) | (N = 4) | (N = 57) | (N = 2) | (N = 113) |
| No exacerbation | 43 (86.0) | 2 (50.0) | 48 (84.2) | 1 (50.0) | 94 (83.2) |
| One or more exacerbation | 5 (10.0) | 2 (50.0) | 9 (15.8) | 1 (50.0) | 17 (15.0) |
| Missing values | 2 (4.0) | 0 | 0 | 0 | 2 (1.8) |
| Triple therapy | (N = 140) | (N = 49) | (N = 101) | (N = 27) | (N = 317) |
| No exacerbation | 94 (67.1) | 25 (51.0) | 69 (68.3) | 14 (51.9) | 202 (63.7) |
| One or more exacerbation | 36 (25.7) | 24 (49.0) | 26 (25.7) | 12 (44.4) | 98 (30.9) |
| Missing values | 10 (7.1) | 0 | 6 (5.9) | 1 (3.7) | 17 (5.4) |
Group 1: 0-1 non-hospitalised and 0 hospitalised exacerbations in the year prior to entry and >300 eosinophils/μL at baseline; Group 2: ≥2 non-hospitalised or ≥1 hospitalised exacerbations in the year prior to entry and >300 eosinophils/μL at baseline; Group 3: 0-1 non-hospitalised and 0 hospitalised exacerbations in the year prior to entry and <100 eosinophils/μL at baseline; Group 4: ≥2 non-hospitalised or ≥1 hospitalised exacerbations in the year prior to entry and <100 eosinophils/μL at baseline